J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
The Journal of New Drugs, 1965; 5:94-101
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silson, J. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Silson, J. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A New Method for Evaluating Antitussive Medications Using the Citric Acid Challenge Technique

John E. Silson M.D.1

1 Food and Drug Research Laboratories, Inc., Maspeth, L. I., N. Y.

A modification of the citric acid aerosol challenge procedure for assessing the potency and duration of action of antitussive medications, representing an improvement on the currently accepted technique, is reported. Instead of determining the number and intensity of coughs induced by a citric acid stimulus well over the threshold, the threshold, itself is measured. A procedure is described in which time can be used to quantitate the citric acid stimulus and to serve as the parameter for evaluating antitussive effectiveness. The method thus far has yielded consistent and significant results with trials on ten subjects, or less, using duplicate runs on occasion, with a special schedule that limits the trials to four a day, spaced at least two hours apart. The procedure shows promise of improve precision in screening new antitussive agents and in evaluating modifications of existing formulations in human subjects.

Note:

The methodology described in this report was developed under a grant from Chesebrough-Pond's, Inc., New York, N. Y. The author acknowledges the technical assistance of B. Barnett, J. Scheimberg, and E. Clemente.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1965 by the American College of Clinical Pharmacology